VENUS REMEDIES LTD. - 526953 - Clarification Regarding Inadvertent Link Of Venus Remedies In News Report Carried By ABP News.
Clarification regarding inadvertent link of Venus Remedies in news report carried by ABP News.03-02-2024
03-02-2024
VENUS REMEDIES LTD. - 526953 - Board Meeting Intimation for Notice Of Board Meeting To Be Held On 14Th February 2024.
VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 ,inter alia, to consider and approve 1. To consider and approve Unaudited Standalone and Consolidated Financial Results for the period ended on 31st December 2023. 2. Any other business with the permission of Chair.02-02-2024
VENUS REMEDIES LTD. - 526953 - Venus Remedies Limited Attains GMP Certification From Libya.
Venus Remedies Limited attains GMP certification from Libya.18-01-2024
VENUS REMEDIES LTD. - 526953 - Venus Remedies Limited Secures New Marketing Authorizations For DOCETAXEL And GEMCITABINE In Malta, Europe.
New Market authorizations for DOCETAXEL and GEMCITABINE in Malta, Europe.12-01-2024
VENUS REMEDIES LTD. - 526953 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of shares information.10-01-2024
VENUS REMEDIES LTD. - 526953 - Closure of Trading Window
Closure of Trading Window for Designated Person from 1st January 2024 till 48 hours from declaration of financial results for the quarter ended on 31st December 2023.27-12-2023
Smallcap pharma stock hits over 8% upper circuit after securing marketing nod for chemotherapy drugs; do you own?
Venus Remedies gained over 8 per cent today after securing marketing authorisation for three variants of chemotherapy drugs in Israel and Colombia21-12-2023
VENUS REMEDIES LTD. - 526953 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliance under regulation 39(3) of LODR.21-12-2023
VENUS REMEDIES LTD. - 526953 - Venus Remedies Achieves Marketing Authorizations For Docetaxel In Israel And Cytarabine In Colombia.
Venus Remedies achieves marketing authorizations for Docetaxel in Israel and Cytarabine in Colombia.21-12-2023
Venus Remedies' R3SET forays into wellness segment; shares rise
The company announced the launch of R3SET Detix Candies, with a blend of natural herbs, that serve as liver detoxifiers and stress relievers20-12-2023